Avanos Medical
Market Cap
US$2.3b
Last Updated
2021/01/15 00:49 UTC
Data Sources
Company Financials +
Executive Summary
Avanos Medical, Inc. operates as a medical technology company that focuses on delivering medical device solutions to improve patients’ quality of life in North America, Europe, the Middle East, Africa, the Asia Pacific, and Latin America. More Details
Rewards
Risk Analysis
Snowflake Analysis
Adequate balance sheet with moderate growth potential.
Similar Companies
Share Price & News
How has Avanos Medical's share price performed over time and what events caused price changes?
Latest Share Price and Events
Stable Share Price: AVNS is less volatile than 75% of US stocks over the past 3 months, typically moving +/- 5% a week.
Volatility Over Time: AVNS's weekly volatility (5%) has been stable over the past year.
Market Performance
7 Day Return
-0.2%
AVNS
-0.4%
US Medical Equipment
0.6%
US Market
1 Year Return
44.4%
AVNS
20.5%
US Medical Equipment
21.0%
US Market
Return vs Industry: AVNS exceeded the US Medical Equipment industry which returned 20.5% over the past year.
Return vs Market: AVNS exceeded the US Market which returned 21% over the past year.
Shareholder returns
| AVNS | Industry | Market | |
|---|---|---|---|
| 7 Day | -0.2% | -0.4% | 0.6% |
| 30 Day | 1.3% | 4.9% | 4.2% |
| 90 Day | 27.1% | 7.4% | 12.4% |
| 1 Year | 44.4%44.4% | 21.5%20.5% | 23.7%21.0% |
| 3 Year | 1.3%1.3% | 73.2%68.8% | 47.4%37.6% |
| 5 Year | 99.6%99.6% | 172.9%152.4% | 131.6%105.9% |
Long-Term Price Volatility Vs. Market
How volatile is Avanos Medical's share price compared to the market and industry in the last 5 years?
Simply Wall St News
8 months ago | Simply Wall St
Does Avanos Medical, Inc. (NYSE:AVNS) Have A Particularly Volatile Share Price?9 months ago | Simply Wall St
Read This Before Selling Avanos Medical, Inc. (NYSE:AVNS) Shares9 months ago | Simply Wall St
Does Avanos Medical, Inc.'s (NYSE:AVNS) CEO Salary Reflect Performance?Valuation
Is Avanos Medical undervalued compared to its fair value and its price relative to the market?
0.2%
Undervalued compared to fair value
Share Price vs. Fair Value
Below Fair Value: AVNS ($48.47) is trading below our estimate of fair value ($48.57)
Significantly Below Fair Value: AVNS is trading below fair value, but not by a significant amount.
Price To Earnings Ratio
PE vs Industry: AVNS is poor value based on its PE Ratio (166.5x) compared to the US Medical Equipment industry average (54.1x).
PE vs Market: AVNS is poor value based on its PE Ratio (166.5x) compared to the US market (21.3x).
Price to Earnings Growth Ratio
PEG Ratio: AVNS is poor value based on its PEG Ratio (2.1x)
Price to Book Ratio
PB vs Industry: AVNS is good value based on its PB Ratio (1.8x) compared to the US Medical Equipment industry average (5x).
Next Steps
Future Growth
How is Avanos Medical forecast to perform in the next 1 to 3 years based on estimates from 7 analysts?
78.1%
Forecasted annual earnings growth
Earnings and Revenue Growth Forecasts
Analyst Future Growth Forecasts
Earnings vs Savings Rate: AVNS's forecast earnings growth (78.1% per year) is above the savings rate (2%).
Earnings vs Market: AVNS's earnings (78.1% per year) are forecast to grow faster than the US market (21.6% per year).
High Growth Earnings: earnings are expected to grow significantly over the next 3 years.
Revenue vs Market: AVNS's revenue (4.7% per year) is forecast to grow slower than the US market (10.2% per year).
High Growth Revenue: AVNS's revenue (4.7% per year) is forecast to grow slower than 20% per year.
Earnings per Share Growth Forecasts
Future Return on Equity
Future ROE: AVNS's Return on Equity is forecast to be low in 3 years time (5.3%).
Next Steps
Past Performance
How has Avanos Medical performed over the past 5 years?
60.2%
Historical annual earnings growth
Earnings and Revenue History
Quality Earnings: AVNS has a large one-off loss of $17.2M impacting its September 30 2020 financial results.
Growing Profit Margin: AVNS became profitable in the past.
Past Earnings Growth Analysis
Earnings Trend: AVNS has become profitable over the past 5 years, growing earnings by 60.2% per year.
Accelerating Growth: AVNS has become profitable in the last year, making the earnings growth rate difficult to compare to its 5-year average.
Earnings vs Industry: AVNS has become profitable in the last year, making it difficult to compare its past year earnings growth to the Medical Equipment industry (-0.3%).
Return on Equity
High ROE: AVNS's Return on Equity (1.1%) is considered low.
Next Steps
Financial Health
How is Avanos Medical's financial position?
Financial Position Analysis
Short Term Liabilities: AVNS's short term assets ($567.6M) exceed its short term liabilities ($179.4M).
Long Term Liabilities: AVNS's short term assets ($567.6M) exceed its long term liabilities ($329.8M).
Debt to Equity History and Analysis
Debt Level: AVNS's debt to equity ratio (19.3%) is considered satisfactory.
Reducing Debt: AVNS's debt to equity ratio has reduced from 56.2% to 19.3% over the past 5 years.
Debt Coverage: AVNS's operating cash flow is negative, therefore debt is not well covered.
Interest Coverage: AVNS's interest payments on its debt are not well covered by EBIT (0.8x coverage).
Balance Sheet
Next Steps
Dividend
What is Avanos Medical current dividend yield, its reliability and sustainability?
Dividend Yield vs Market
Notable Dividend: Unable to evaluate AVNS's dividend yield against the bottom 25% of dividend payers, as the company has not reported any recent payouts.
High Dividend: Unable to evaluate AVNS's dividend yield against the top 25% of dividend payers, as the company has not reported any recent payouts.
Stability and Growth of Payments
Stable Dividend: Insufficient data to determine if AVNS's dividends per share have been stable in the past.
Growing Dividend: Insufficient data to determine if AVNS's dividend payments have been increasing.
Current Payout to Shareholders
Dividend Coverage: Insufficient data to calculate payout ratio to determine if its dividend payments are covered by earnings.
Future Payout to Shareholders
Future Dividend Coverage: No need to calculate the sustainability of AVNS's dividend in 3 years as they are not forecast to pay a notable one for the US market.
Next Steps
Management
How experienced are the management team and are they aligned to shareholders interests?
1.0yrs
Average management tenure
CEO
Joe Woody (54 yo)
3.58yrs
Tenure
US$5,023,674
Compensation
Mr. Joseph F. Woody, also known as Joe, has been Chief Executive Officer and Director of Avanos Medical, Inc. (formerly known as Halyard Health, Inc.) since June 26, 2017. Mr. Woody served as the Chief Exe...
CEO Compensation Analysis
Compensation vs Market: Joe's total compensation ($USD5.02M) is above average for companies of similar size in the US market ($USD3.85M).
Compensation vs Earnings: Joe's compensation has been consistent with company performance over the past year.
Leadership Team
| Name | Position | Tenure | Compensation | Ownership |
|---|---|---|---|---|
| CEO & Director | 3.58yrs | US$5.02m | 0.049% $ 1.1m | |
| Senior Vice President of Business Strategy | 1yr | US$911.19k | 0.081% $ 1.9m | |
| Senior Vice President of International | 2.75yrs | US$836.80k | 0.027% $ 633.6k | |
| Senior Vice President of Global Supply Chain & Procurement | 2.08yrs | US$1.04m | 0% $ 0 | |
| Senior VP & CFO | 1yr | no data | 0% $ 0 | |
| VP, Controller & Chief Accounting Officer | no data | no data | 0.049% $ 1.1m | |
| VP of FP&A and Investor Relations and Treasurer | no data | no data | no data | |
| Senior VP | 0.25yr | no data | no data | |
| Senior VP and Chief Ethics & Compliance Officer | 0.33yr | no data | no data | |
| Senior VP & Chief Human Resources Officer | 6.25yrs | US$1.03m | no data | |
| Senior Vice President of Global R&D | no data | no data | no data | |
| Senior VP & GM of Pain Franchise | 0.42yr | no data | no data |
1.0yrs
Average Tenure
54yo
Average Age
Experienced Management: AVNS's management team is not considered experienced ( 1 years average tenure), which suggests a new team.
Board Members
| Name | Position | Tenure | Compensation | Ownership |
|---|---|---|---|---|
| CEO & Director | 3.58yrs | US$5.02m | 0.049% $ 1.1m | |
| Independent Director | 6.25yrs | US$250.00k | 0.061% $ 1.4m | |
| Independent Director | 5.08yrs | US$265.00k | 0.066% $ 1.5m | |
| Independent Director | 6.25yrs | US$270.00k | 0.061% $ 1.4m | |
| Independent Director | 6.25yrs | US$250.00k | 0.061% $ 1.4m | |
| Independent Chairman | 0.67yr | US$265.00k | 0.082% $ 1.9m | |
| Independent Director | 6.25yrs | US$265.00k | 0.061% $ 1.4m | |
| Independent Director | 5.92yrs | US$250.00k | 0.059% $ 1.4m | |
| Director | 0.75yr | no data | no data |
5.9yrs
Average Tenure
63yo
Average Age
Experienced Board: AVNS's board of directors are considered experienced (5.9 years average tenure).
Ownership
Who are the major shareholders and have insiders been buying or selling?
Insider Trading Volume
Insider Buying: Insufficient data to determine if insiders have bought more shares than they have sold in the past 3 months.
Recent Insider Transactions
Ownership Breakdown
Dilution of Shares: Shareholders have not been meaningfully diluted in the past year.
Top Shareholders
Company Information
Avanos Medical, Inc.'s company bio, employee growth, exchange listings and data sources
Key Information
- Name: Avanos Medical, Inc.
- Ticker: AVNS
- Exchange: NYSE
- Founded: 2014
- Industry: Health Care Supplies
- Sector: Healthcare
- Market Cap: US$2.305b
- Shares outstanding: 47.55m
- Website: https://avanos.com
Number of Employees
Location
- Avanos Medical, Inc.
- 5405 Windward Parkway
- Suite 100 South
- Alpharetta
- Georgia
- 30004
- United States
Listings
| Ticker | Exchange | Primary Security | Security Type | Country | Currency | Listed on |
|---|---|---|---|---|---|---|
| AVNS | NYSE (New York Stock Exchange) | Yes | Common Stock | US | USD | Oct 2014 |
| 8HH | DB (Deutsche Boerse AG) | Yes | Common Stock | DE | EUR | Oct 2014 |
Biography
Avanos Medical, Inc. operates as a medical technology company that focuses on delivering medical device solutions to improve patients’ quality of life in North America, Europe, the Middle East, Africa, the...
Company Analysis and Financial Data Status
| Data | Last Updated (UTC time) |
|---|---|
| Company Analysis | 2021/01/15 00:49 |
| End of Day Share Price | 2021/01/14 00:00 |
| Earnings | 2020/09/30 |
| Annual Earnings | 2019/12/31 |
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.